2,755
Participants
Start Date
November 5, 2018
Primary Completion Date
June 7, 2021
Study Completion Date
June 7, 2021
Iodixanol
Iodixanol 270 mgI/ml or 320 mg I/ml injection will be administered as part of clinical practice according to the judgment of the site with regard to medical need.
Kaifeng Central Hospital, Kaifeng
The Second Affiliated Hospital of Chongqing Medical University, Chongqing
Lanzhou University Second Hospital, Lanzhou
The First Hospital of Lanzhou University, Lanzhou
Dongguan Kanghua Hospital, Guangdong
The First Affiliated Hospital of Jinan University, Guangzhou
The First Affiliated Hospital, Sun Yat-sen University, Guangzhou
Affiliated Hospital of Guangdong Medical University, Zhanjiang
Hebei General Hospital, Shijiazhuang
Shijiazhuang First Hospital Central Hospital Campus, Shijiazhuang
Shijiazhuang First Hospital, Shijiazhuang
The Second Hospital of Hebei Medical University, Shijiazhuang
The First Affiliated Hospital of Henan University of CM, Zhengzhou
Wuhan Asia Heart Hospital, Wuhan
Wuhan Central Hospital, Wuhan
The Third Xiangya Hospital of Central South University, Changsha
Nanjing Jiangning Hospital, Nanjing
People's Hospital of Jiangsu Province, Nanjing
China-Japan Friendship Hospital of Jilin University, Changchun
The Second Hospital of Jilin University, Changchun
The People's Hospital of Liaoning Province, Shenyang
Ankang City Central Hospital, Ankang
Linzi District People's Hospital, Linzi
Shanxi Province Fenyang Hospital, Fenyang
Shanxi Cardiovascular Hospital, Taiyuan
Taiyuan Central Hospital, Taiyuan
Xi'an No.3 Hospital, Xi’an
Sichuan Provincial People's Hospital, Chengdu
Ningbo First People's Hospital, Ningbo
Shaoxing Hospital of Zhejiang University, Shaoxing
Peking University First Hospital, Beijing
Wangjing Hospital of CACMS, Beijing
Shanghai Tongren Hospital, Shanghai
Shanghai Zhongshan Hospital, Shanghai
Tianjin Chest Hospital, Tianjin
Seoul National University Bundang Hospital, Seoul
Lead Sponsor
GE Healthcare
INDUSTRY